Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes
Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes
Glucose-induced insulin secretion is often diminished in hyperglycaemic patients with type 2
 diabetes. The investigators examined, whether chronic basal insulin treatment with insulin
 glargine lead to improvements in glucose-induced insulin secretion.
14 patients with type 2 diabetes on previous metformin therapy were examined before and after
 eight weeks of treatment with insulin glargine, aimed to normalize fasting glycaemia.
 Intravenous glucose tolerance tests were performed with and without previous adjustment of
 fasting glucose levels by means of a 3-hour intravenous insulin infusion.
Inclusion Criteria:

 1. Age between 18 and 75 years, inclusive

 2. BMI-range 27-50 kg/m²

 3. patients with type 2 diabetes presenting with fasting hyperglycaemia (>126mg/dl) on
 metformin treatment

 Exclusion Criteria:

 1.Pre-existing insulin therapy, treatment with sulphonylureas, glitazones, 2.glinides,
 DPP-4-inhibitors or exenatide 3.patients with type 1 diabetes 4.Patients are investigator
 site personnel directly affiliated with the study, or are immediate family of investigator
 site personnel directly affiliated with the study. Immediate family is defined as a spouse,
 parent, child, or sibling, whether biological or legally adopted.

 5. Females of childbearing potential who are pregnant, breast-feeding or intend to become
 pregnant or are not using adequate contraceptive methods (adequate contraceptive measures
 include sterilisation, hormonal intrauterine devices, oral contraceptives, sexual
 abstinence or vasectomised partner). A male subject who is sexually active and has not been
 surgically sterilised must be informed that he must either use a condom during intercourse,
 ensure that his partner practices contraception, or he must refrain from sexual intercourse
 during the trial and until 1 month after completion of the trial. This is to prevent the
 possibility of a pregnancy from spermatocytes that can potentially be damaged by trial
 medication. It is strongly recommended that the female partners use a highly effective
 contraception (Pearl Index < 1%).

 6. Patients have participated in an interventional medical, surgical, or pharmaceutical
 study (a study in which an experimental, drug, medical, or surgical treatment was given)
 within 30 days prior to screening. This criterion includes drugs that have not received
 regulatory approval for any indication at the time of study entry.

 7. Patients have alcohol consumption (>20 g daily for males and >10 g daily for females) 8.
 Patients have alanine aminotransaminase (ALT) greater than ten times the upper limit of the
 reference range.

 9.Patients are undergoing therapy for a malignancy, other than basal cell or squamous cell
 skin cancer.

 10. Patients have cardiac disease that is Class III or IV, according to the New York Heart
 Association criteria.

 11. Patients have a history of renal transplantation or are currently receiving renal
 dialysis or have serum creatinine >1.8 mg/dL for males and greater than or equal to >1.5
 mg/dL for females. 12.Patients have known hemoglobinopathy or chronic anemia 13.Patients
 are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
 (excluding topical and inhaled preparations) or have received such therapy within 2 weeks
 immediately prior to screening.

 14. Patients have any other condition (including known drug or alcohol abuse or psychiatric
 disorder) that precludes them from following and completing the protocol, in the opinion of
 the investigator.

 15. Patients fail to satisfy the investigator of suitability to participate for any other
 reason.